Validations: Mitigation Changes & Justifications

Process Water Changes: Chloramination Controls and Verification Process Water Changes: Chloramination Controls and Verification The pharmaceutical industry faces increasing scrutiny regarding the safety of medications, especially concerning impurities such as nitrosamines. Various regulatory authorities, including the FDA, EMA, and MHRA, have set limits on acceptable nitrosamine levels. The presence of nitrosamines, specifically N-Nitrosodimethylamine (NDMA), has raised concerns, mandating robust risk…

Cleaning Strategy Impacts: Detergents and Carryover Risks Cleaning Strategy Impacts: Detergents and Carryover Risks In the pharmaceutical industry, ensuring the safety and efficacy of products is paramount. Among various contaminants, nitrosamines have emerged as potential carcinogens, prompting stringent regulations and assessments such as the ICH M7 guidelines. One critical area of focus is the cleaning strategy of manufacturing equipment, which…

Packaging Interventions: Barriers, Foils, and Inks Packaging Interventions: Barriers, Foils, and Inks Introduction to Packaging Interventions in Pharmaceuticals The pharmaceutical industry has been increasingly focused on the mitigation of nitrosamines in drug products due to the associated health risks linked to their presence. Nitrosamines, particularly N-Nitrosodimethylamine (NDMA), are classified as probable human carcinogens, even at low levels. As regulatory bodies…

Mitigation Strategy: Eliminating Precursors and Nitrosating Agents Introduction to Nitrosamine Risk Assessment Nitrosamines are a class of chemical compounds known for their potential carcinogenic effects. The concern surrounding these substances has intensified, prompting regulators globally, including the US FDA, EMA, and MHRA, to establish guidelines addressing nitrosamine contamination in pharmaceutical products. This tutorial guides pharma professionals through the step-by-step process…

Route Redesign: Alternative Reagents, Solvents, and Conditions Understanding Nitrosamine Risk Assessment Nitrosamines are a class of compounds that can pose serious health risks, including cancer, when present in pharmaceuticals. The rising concern over nitrosamine impurities has prompted stringent regulatory guidelines from agencies such as the US FDA, EMA, and MHRA. As a result, pharmaceutical companies are required to conduct comprehensive…